Research Article
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
Table 1
Participant characteristics.
| ||||||||||||||||||||||||||||||||||||||||||||||||
Values are expressed as or median (interquartile range). BMI: body mass index; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; CPR: C-peptide; CPI: C-peptide index; ΔCPR: C-peptide immunoreactivity after glucagon stimulation; UACR: urine albumin to creatinine ratio; eGFR: estimated glomerular filtration rate; IDeg: insulin degludec before switching; IDegLira: insulin degludec/liraglutide after switching; SGLT2: sodium-glucose cotransporter 2. |